Meeting
2018 Genitourinary Cancers Symposium
Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.
Authors
Edoardo Francini
Sapienza University of Rome, Rome, Italy
Edoardo Francini , Kathryn P. Gray , Grace Shaw , Carolyn Evan , Anis Hamid , Caitlin E Perry , Philip W. Kantoff , Mary-Ellen Taplin , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 203)
DOI
10.1200/JCO.2018.36.6_suppl.203
Abstract #
203
Poster Bd #
K1
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).
First Author: Cecile Vicier
Poster
2016 Genitourinary Cancers Symposium
Sequencing of treatments in metastatic CRPC for patients who have completed all therapeutic interventions.
First Author: Allie E. Steinberger
Poster
2021 ASCO Annual Meeting
First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).
First Author: Kim van der Zande
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans